PROGRAM OVERVIEW

This program will equip students with solid theoretical and systematic professional knowledge in molecular medicine, biomedical engineering, and related fields. Graduates of this program will have the opportunity to undertake independent scientific research, allowing them to understand the current status and future trends of medicine/biomedical engineering, and write and communicate in English.

MAIN RESEARCH FIELDS:

1. Biomedical information

Apply biomedical engineering techniques and methods to collect, analyze and evaluate health-related biomedical information, establish disease risk prediction and early warning models, explore the underlying reasons of disease pathogenesis, and conduct intervention studies.

2. Cell and tissue engineering

Conduct research on various types of stem cell and bioscaffold materials, and learn how to apply tissue engineering and regeneration technologies to acute and chronic injuries and diseases; conduct research using cell engineering and nanomaterial labeling technologies based on modern gene technology; perform in vivo and in vitro cell tracing and monitoring; and develop new sources of stem cells for research and industrialization amplification technologies, including the development of 3D culture and amplification and bioreactor systems.

3. Systematic Biomedical:

Harness biophysical, biochemical, bioinformatic and systems biology approaches to study human aging and major diseases such as cancer, cardiovascular and cerebrovascular diseases, metabolic diseases, and infectious diseases; use cells, tissues, organs to conduct translational medicine research into human disease mechanisms at multiple levels, and develop personalized and precise diagnostic and treatment approaches.

CORE COURSES

Frontiers in Biomedical Engineering, Biomedical Image Analysis, Lecture on Pattern Recognition Front, Advanced Cell Biology and Disease, Biochemistry and Molecular Biology.

CAREER PROSPECTS

There is a wide spectrum of career paths that can follow from obtaining a PhD in Biomedical Engineering, including but not limited to:

Biomedical Scientist/Researcher Biomedical scientists and researchers, in both clinical and/or research environments, conduct research that aims to improve human health by carrying out scientific tests to find solutions to medical/clinical problems. They research information that aids in the development of biomedical technology and test products so that they are safe and effective for consumers.

Biomaterials DeveloperBiomedical engineers may develop biomaterials based on either natural living tissue or artificial materials, for use in the human body. Tissue engineering, biomedical implant development, drug delivery and nano implants are all areas that a biomaterials developer may work in. Biomaterials can be used to either repair or replace lost function to the body, or to detect and image disease.

Biomedical Artificial Intelligent (AI) Researcher or Developer AI technology is rewiring many parts of society. How medical/clinical procedures and philosophies will be affected by AI is a thrilling frontier for exploration. A career in this field will involve you not only in science and technology, but also in areas of ethics, finance, and regulation.

Rehabilitation EngineerBiomedical engineers who work in a field dedicated to rehabilitation often work on diverse projects. These can range from mechanical equipment that helps patients regain the ability to walk, to virtual reality systems that aid in limb mobility. Rehabilitation engineers may also create custom solutions based on unique needs or research improvements that can form the basis of a novel rehabilitation technology.

Medical Device/Technology Developer

Medical technology can refer to the hardware and software that help manufacture medical devices, as well as to the technology that is an integral part of those devices. Medical technology professionals with biomedical engineering backgrounds may specialize in bioinstrumentation, or the use of bioelectronic/biomechanical/biochemical instruments to record or transmit physiological information in vivo and/or in vitro.

Consultation

Email:   molmed.hsc@szu.edu.cn                

英文名

HaiqiangWu

联系邮箱

wuhq@szu.edu.cn

中文简介

博士，教授，博士生导师，深圳市高层次人才等。主要研究领域为药物化学和化学生物学，研究方向涉及AD、肿瘤等系统性复杂疾病药物作用新靶点的发现、网络靶向新药物分子的设计、合成、功能及作用分子机制研究等。先后主持国家自然科学基金面上项目、广东省社会发展领域科技计划项目、深圳市“新技术、新产品、新工艺”项目、深圳市科技计划项目、深圳市国际合作项目等多项，已在J Med Chem等国际重要刊物上发表学术论文70多篇，申请新药国际专利PCT 1 项，授权新药国家发明专利9项，实审新药发明专利20项，获得广东省科学技术进步奖（二等，2010年、2017年）2项，深圳市科技创新奖（高等院校类，2008年）1项等。

英文简介

Ph.D., Professor, Ph.D. Supervisor. I am a professor in Medicinal Chemistry and Chemical Biology. My lab mainly focuses on the design, synthesis, and evaluation of novel molecules targeting Glutaminyl cyclase, iso-Glutaminyl cyclase and other proteins as potential anti-AD and anti-cancer agents. I pay particular attention in exploring the mechanism underlying the regulation of up-regulated QC and iso-QC in the initiation of AD and caners at the early stage. Research in my lab has been continuously supported by 4 regular grants of the National Natural Science Foundation in China (NSFC), 1 grant of Basic Research Foundation of Guangdong, 4 grants of Basic Research Foundation of Shenzhen, etc since 2015. I have published more than 70 papers in the peer-reviewed professional journals. I am currently mentoring 1 postdoctoral fellows, 2 PhD candidates and 17 MSc candidates.

英文名

Jie Liu

联系邮箱

liuj@szu.edu.cn

中文简介

刘杰教授长期从事正常与疾病（心肌肥大、缺血/再灌注损伤等）心脏功能及其调节机制的研究。利用分子生物学、光学成像及膜片钳等技术从分子层面、钙信号和电生理学等方面阐明疾病心脏结构和电重构的机制。提出了MG53、Rad等新基因在心肌钾离子通道功能调节中的作用和病理条件下与心律失常发生的关系，以及Himf等新基因引起心衰发生的机制和治疗新策略。以通讯作者（含共同）在Circ、Circ Res、Hypertension、Cardiovasc Res、Basic Res Cardiol等杂志发表论文，累计发表SCI论文50余篇。主持多项国家自然科学基金面上项目、广东省自然科学基金面上项目及深圳市基础研究项目。并获广东省科技进步一等奖、教育部自然科学一等奖和广东省自然科技奖三等奖，申请专利3项。

英文简介

 Professor Liu is mainly engaged in the study of cardiac function and its regulatory mechanisms under physiological and pathological conditions (cardiac hypertrophy, ischemia/reperfusion injury, etc.). Molecular biology, optical imaging and patch clamp technologies are used in the study to elucidate the mechanisms underlying the pathological remodeling in diseased hearts. She presented the novel roles of the genes such as MG53, Rad and Himf in the regulation of cardiac excitation-contraction coupling and their contributions to the development cardiac arrhythmia and heart failure. She has published papers in journals such as Circ, Circ Res, Hypertension, Basic Res Cardiol as the corresponding author. She has presided over a number of projects of National Natural Science Foundation, Guangdong Natural Science Foundation and Shenzhen Basic Research Project. She also won the first prize of Guangdong Science and Technology Progress, the first prize of Natural Science of the Ministry of Education and the third prize of Guangdong Natural Science and Technology Award, and applied for 3 patents.

英文名

Baohua Liu

联系邮箱

ppliew@szu.edu.cn

中文简介

刘宝华，北京大学学士，香港大学博士，国家杰青、优青，广东省优粤人才，深圳市孔雀人才，以诚为本赢在信誉9001cc教授/博导，基础医学院院长，国家生化工程技术研究中心（深圳）主任，深圳市系统衰老与主动健康重点实验室主任，亚洲衰老研究学会秘书长，中国老年医学学会基础与转化医学分会副会长，中国生物物理学会衰老生物学专业委员会副会长，中国老年学和老年医学学会老年病学分会常务委员，中国细胞生物学会衰老细胞生物学分会常务委员。研究团队专注于衰老机制与干预策略研究，近五年主持杰青、优青、重点、重大研究计划、国际（地区）合作等国家级项目共21项，在Nature Medicine, Cell Metabolism, Nature Metabolism等国际顶级期刊发表学术论文，为儿童早衰症的临床治疗提供重要依据。

英文简介

Dr Baohua Liu earned his B.S. degree from Peking University in 1999, and Ph.D. degree in Department of Biochemistry, the University of Hong Kong in 2007. He completed postdoctoral training at the University of Hong Kong and was promoted to Research Assistant Professor in 2011. In 2014, Dr Liu joined Shenzhen University Health Science Center as a Distinguished Professor. During his career, Dr Liu has received awards including Li Ka Shing Prize, the National One Thousand Young Talents Award and the National Excellent Young Researcher Award. His research interests are centered on mechanisms and interventions of aging.

英文名

Suping Zhang

联系邮箱

s9zhang@szu.edu.cn

中文简介

清华大学博士，美国加州大学圣地亚哥分校博士后，以诚为本赢在信誉9001cc副教授，张博士长期致力于肿瘤生物学及免疫靶向治疗新药的研究，利用细胞生物学、生物化学、分子生物学、免疫学、生物信息学等多学科分析方法，研究肿瘤发生、发展、转移及复发的机制及寻找新的治疗靶标，据此开发靶向消除肿瘤细胞或改变其微环境的免疫治疗新药有望治愈癌症。到目前为止，张博士主要开发的进入临床试验阶段的用于免疫治疗的一类新药有两个；发表高水平学术论文25篇，包括通讯作者论文或第一作者论文14篇（含三篇PNAS），总引用次数超过1500次。拥有发明专利6项，其中一项已经商业化。承担国家重点研究计划、国家自然科学基金面上项目和深圳市孔雀创新团队项目等10余项。2011年获美国血液学年会摘要成就奖。

英文简介

Dr Zhang obtained her Ph.D degree in Tsinghua University (major: molecular cell biology)，completed her post-doc training in immunology at University of California, San Diego and then was recruited as associated professor in School of Medicine, Shenzhen University. Dr Zhang’s research interests lie in: Using multidisciplinary approach of molecule cell biology, cell biology, biochemistry, immunology and bioinformatics to investigate the molecular mechanism underlying tumor initiation, metastasis and relapse,  and develop novel small compounds and immunological therapeutics for patients with cancer. To date, Dr. Zhang has developed two novel anti-cancer drugs which are under clinical investigation currently. She had co-authored 25 publications which include three papers published on PNAS and one one Oncogene as first or corresponding author. She had 6 patents and one of them already was commercialized. She has been funded by National Key R&D plan, National Natural Science Foundation of China (NSFC), Shenzhen Peacock Innovation Team Grant and so on. She had been awarded “Excellent Abstract Achievement” by American Society of Hematology (ASH) at 2011.

英文名

SHU, Xingsheng

联系邮箱

shu@szu.edu.cn

中文简介

舒兴盛，博士，副教授，深圳市海外高层次人才（C类）。2008年于北京大学生命科学学院获学士学位，2012年于香港中文大学医学院临床肿瘤学系获博士学位，现任以诚为本赢在信誉9001cc医学部基础医学院副教授。舒兴盛博士长期致力于肿瘤中的表观遗传调控异常的机制及相关的转化治疗研究，目前共发表SCI论文三十余篇，被引用1100余次，H-index为18，其中近5年在PNAS、Oncogene、Journal of Pathology、Theranostics等高水平学术期刊以通讯或第一作者发表论文14篇，获得中国发明专利授权两项，并主持完成多项国家和省市级项目，目前有包括国自然面上项目在内的多个项目在研。更多研究情况请参看链接：https://www.ncbi.nlm.nih.gov/myncbi/xingsheng.shu.1/bibliography/public/。

英文简介

    Dr. Xing-sheng Shu received his B.S. degree from the School of Life Sciences, Peking University in 2008 and his Ph.D. degree from the Department of Clinical Oncology, The Chinese University of Hong Kong in 2012. He is currently an Associate Professor at the School of Medicine, Shenzhen University. Dr. Shu has been working on abnormal epigenetic and transcriptional regulation in cancer and related translational research for cancer therapy. He has published more than 30 SCI papers with more than 1100 citations and an H-index of 18, including more than 10 papers in PNAS, Oncogene, Journal of Pathology, Theranostics and other high impact journals in recent 5 years as corresponding or first author. He also holds two invention patents, and completed many national and provincial research projects. For more information about his research, please refer to the link: https://www.ncbi.nlm.nih.gov/myncbi/xingsheng.shu.1/bibliography/public/.

英文名

Ying Ying

联系邮箱

yingying@szu.edu.cn

中文简介

应颖，博士，教授，博士生导师，深圳市海外高层次B类人才。2007年获德国海德堡大学分子生物学博士学位，2008-2010于香港中文大学医学院从事博士后研究工作，现任深大医学部基础医学院副院长兼生理学系副主任。长期致力于表观遗传变异所致的转录调控异常参与代谢性、神经退行性疾病及肿瘤的发生发展的分子机制及转化治疗研究。主持完成包括国家自然科学基金在内的多项国家和省市级项目。以第一或通讯作者（含共同）在Molecular Neurodegeneration, PNAS，Oncogene, Theranostics, Journal of Pathology等国际著名期刊上发表论文20余篇。

英文简介

Prof. Ying Ying (MD, PhD) is the vice president of College of Basic Medicine and also the vice dean of the Department of Physiology at Shenzhen University Health Science Center. She obtained her PhD from University of Heidelberg, Germany, in 2007. Following postdoctoral training at The Chinese University of Hong Kong, she became a Principal Investigator and Professor at School of Medicine, Shenzhen University Health Science Center in China. Her research focuses on epigenetic dysregulation in contribution to the pathogenesis of metabolic and neurodegenerative diseases as well as colorectal cancer. She has presided over the completion of a number of research projects including the National Natural Science Foundation of China. As the corresponding author or first author, she has published over 20 research articles in top journals (i.e. Molecular Neurodegeneration, PNAS, Oncogene, Theranostics, Journal of Pathology, etc.).

英文名

Song Wu

联系邮箱

wusong@szu.edu.cn

中文简介

吴松，医学博士，教授，博士生导师，以诚为本赢在信誉9001cc附属华南医院院长，以诚为本赢在信誉9001cc医院管理研究院院长，以诚为本赢在信誉9001cc泌尿外科研究所所长，深圳市泌尿外科质量控制中心主任。主要从事泌尿系统疾病发生机制研究、临床诊疗转化、智能诊断体系构建等研究与开发工作。同时，致力于医院精细化管理和卫生体制改革研究，建设高水平智慧型、研究型医院。国家重点研发计划首席科学家，国家优青，国自然基金重点项目负责人，中国医师协会泌尿外科分会委员、广东省医学会精准医学与分子诊断分会副主任委员、深圳市医学会人工智能机器人专委会主任委员等职。获全国五一劳动奖章、广东省科技创新领军人才、广东省医学领军人才、深圳科技进步一等奖等。

英文简介

Song Wu

MD, Professor, Doctoral Supervisor, President of South China Hospital of Shenzhen University, President of Hospital Management Research Institute of Shenzhen University, Director of Urology Institute of Shenzhen University, Director of Shenzhen Urology Quality Control Center.

Wu’s research is mainly focused on the pathogenetic mechanism of urinary system diseases and develop intelligent diagnosis system for clinical transformation. Wu is also committed to the research of refined management of hospitals and promote health system reformation with the aim to build a smart, high-level and research-oriented hospital.

Wu is the Chief Scientist of National Key R&D Program, National Excellent Young Scientist, Leader of Key Project for National Natural Science Foundation of China, Member of Urology Branch of Chinese Medical Doctor Association, Deputy Director of Precision Medicine and Molecular Diagnosis Branch of Guangdong Medical Association, Chairman of the Shenzhen Medical Association Artificial Intelligence Robot Special Committee, et al. He has won the National May 1st Labor Medal, the Leading Talent in Science and Technology Innovation in Guangdong Province, the Leading Medical Talent in Guangdong Province, and the First Prize of Shenzhen Science and Technology Progress Award.

英文名

Huiren Tao

联系邮箱

huiren_tao@163.com

中文简介

脊柱骨病科主任医师、医学博士教授、博士研究生导师、硕士研究生导师。从事脊柱外科工作近30年，对于脊柱疾病的诊治有丰富的临床经验，现已主刀完成近万台各类脊柱手术。主刀完成了国内首例极重度强直性脊柱炎患者（“3-on”折叠人）的救治和L5椎体切除术治疗腰椎5度滑脱等，是全国治疗脊柱畸形例数最多、效果最好的医生之一。享受深圳市政府特殊津贴，是深圳市地方级领军人才，2019年获得深圳市卫生健康十大杰出贡献者荣誉称号。承担国家自然科学基金项目3项、省部级基金项目3项。在国际脊柱外科领域顶尖专业权威杂志Spine等发表SCI论文20余篇，有1400万元的科研经费。

英文简介

  Huiren Tao, Chief Physician, Doctor of Medicine Professor, Doctoral Tutor, Master Tutor of Spine and Osteopathy. He has been engaged in spinal surgery for nearly 30 years and has extensive clinical experience in the diagnosis and treatment of spinal diseases,and completed nearly 10,000 spinal surgeries.

He completed the treatment of the first domestic patient with extremely severe ankylosing spondylitis ("3-on" folding person) and L5 vertebral resection to treat lumbar spondylolisthesis and other operations. He’s one of the doctors that has the largest number of cases and the most effective treatment of spinal deformity all over the country. He is a local-level leading talent in Shenzhen, enjoys special allowances from the Shenzhen government and was awarded the honorary title of Shenzhen's Top Ten Outstanding Contributors to Health in 2019. Undertake 3 National Natural Science Foundation projects and 3 provincial and ministerial fund projects. He has published more than 20 SCI papers in top professional and authoritative journals in the field of spine surgery, such as Spine, and has 14 million yuan in scientific research funding.

英文名

Xueqing Wu

联系邮箱

Wuxueqing.37@hotmail.com

中文简介

教授、主任医师、博士生导师、博士后导师、深圳市海外高层次人才B类，深圳市实用型临床医学人才I类。现任中国妇幼健康专业委员会委员，广东省基层医药学会生殖妇科副主委等职。担任《生殖医学》编委。主要研究方向：1.早期不良事件对生殖调节轴的影响及机制研究；2.妇科肿瘤表观遗传学分子机制研究。主持国自然基金项目2项和省部级科研项目8项。以第一作者和通讯作者在AJOG, BJOG等期刊发表论文50余篇，参编《妇产科检验诊断》等专业论著（教材）2部。以第一完成人获浙江省医药卫生进步奖三等奖和温州市科学技术奖三等奖。承担本科生《妇产科学》和研究生《妇产科进展》课程教学工作。培养研究生20余名。

英文简介

lProfessor, chief surgeon, graduate student advisor, postdoctoral advisor

lShenzhen Overseas High-level Talent (B class), Shenzhen practical type of Clinical Medicine Talent (I class).

Served in several academic societies, including: member of China maternal and child health committee; vice-chairman of reproductive gynecology department of Guangdong provincial association of primary medicine; editorial board of journal of reproductive medicine.

lMain research interests: 1. The effect of early adverse events on the reproductive regulation axis and its mechanism; 2. Molecular mechanism of Epigenetics in gynecological tumors.

lPrincipal Investigator of 2 national natural fund projects and 8 provincial and ministerial-level scientific research projects.

lPublished more than 50 papers in journals such as AJOG, BJOG and so on as the first author and corresponding author.

lthe third prize of the Zhejiang Medical and Health Progress Award; the third prize of the Wenzhou Science and Technology Award.

lTeaching of the undergraduate course “Obstetrics & Gynecology” and the postgraduate course “Advances in Obstetrics & Gynecology”.

lTraining more than 20 graduate students.

英文名

Peng Gong

联系邮箱

doctorgongpeng@szu.edu.cn

中文简介

巩鹏，教授、主任医师、博士/博士后合作导师、以诚为本赢在信誉9001cc总医院副院长、普外科主任。从医27年来，巩鹏教授一直致力于消化道肿瘤的临床与基础研究。先后参与撰写多项中英文临床指南与教材；在国家自然基金、高等学校博士学科点专项科研基金、省自然科学基金等十余项基金资助下，围绕消化道肿瘤发病及耐药机制先后在《Journal of Advanced Research》、《Theranostics》以及《Oncogene》等国内外期刊杂志发表论文150余篇，申请专利8项。上述研究成果先后获得省、市级科技进步奖10余项。

英文简介

I am the chief physician and the deputy dean of Shenzhen University General Hospital. I have two excellent teams which focus on clinical and basic cancer research. As the co-author, I wrote a number of clinical guidelines and textbooks in both Chinese and English. Supported by more than ten funds such as the National Natural Science Foundation of China, the Special Scientific Research Fund for Doctoral Programs in Higher Education, and the Provincial Natural Science Foundation, I try to clarify the mechanism of the gastrointestinal tumors and drug resistance. I discovered that the tumor environment plays an important role in tumor development and chemotherapeutic drug resistance. For example, we observed that the levels of macrophages and activated dendritic cells in tumor tissues were significantly higher than that in para-tumor tissues. Macrophages, gamma delta T cells and naive CD4 T cells were independent predictive factors of a poor outcome for pancreatic ductal adenocarcinoma patients. Subsequently, I observed that autophagy and Hippo-YAP1 signaling pathway, two processes, has been reported to regulate the pathophysiology of cancer and the sensitivity to chemotherapy. Bafilomycin A1, an inhibitor of autophagy, could induce caspase-independent cell death via targeting of autophagy and MAPK pathways. In addition, we found tumor suppressor Spred2 interaction with LC3 promotes autophagosome maturation and induces autophagy-dependent cell death. Currently, I have mentored 4 post doctors, 4 PhD candidates, and 30 MSc candidates; we published more than 150 papers.

英文名

Guohui Nie

联系邮箱

nieguohui@email.szu.edu.cn

中文简介

深圳市第二人民医院院长，主任医师，博士生导师。从事耳鼻咽喉科临床及基础研究37年余，主要研究听觉及平衡相关疾病的基础和临床，鼻咽癌早筛早诊断及治疗相关研究。先后承担国家、省市级课题20余项；主编专业书籍1部，参编2部，授权专利15项；至今在国内外期刊发表论文80余篇。先后获得“深圳市劳动模范”及“广东省五一劳动奖章”。现任中华医学会耳鼻咽喉-头颈外科学分会委员会委员，广东省医学会耳鼻咽喉学分会副主任委员，广东省医师协会耳鼻咽喉学分会常委，深圳市医学会耳鼻咽喉专业委员会主任委员等学术任职。

英文简介

Guohui Nie:  The director of Shenzhen Second People’s Hospital, a chief physician and a doctoral supervisor.

Guohui Nie has been engaged in the fundamental  and clinical research on  otolaryngology for more than 37 years, with professional theoretical knowledge and proficient clinical surgery skills. His  research  is focused on fundamental  and clinical research dealing with  hearing and balance problems, early diagnosis and treatment for nasopharyngeal carcinoma. Prof. Nie has undertaken over 20 national, provincial and municipal projects, 3 professional book (editor- in -chief of 1 book, co -editor of 2 books), and 15  licensed patents. Up to now, he has published more than 80 papers at home and abroad and has successively been honoured as the "Shenzhen Model Worker" and the "May-First Labor Medal of Guangdong ".

Currently, Prof. Nie is the member of the Committee of Otolaryngology- Head and Neck Surgery Branch of Chinese Medical Association;the Vice Chairman of Otolaryngology Branch of Guangdong Medical Association;the member of the Standing Committee of Otolaryngology Branch of Guangdong Medical Doctor Association；the Chairman of the Otolaryngology Committee of Shenzhen Medical Association and so on.

英文名

Shi Chen

联系邮箱

shichen@email.szu.edu.cn

中文简介

主要开展表观遗传相关研究，利用最新发展的前沿技术，对细胞或病原菌基因组进行精确地鉴定、修饰和编辑，鉴定细菌宿主对病毒的防御机制，解析这些表观遗传学修饰或基因组改造对细胞生命活动或对病原菌侵染能力的影响。该方向以通讯或共通讯作者发表Nature Catalysis，PNAS 3篇, Nature Communications 4篇, Advanced Science，Angew Chem Int Ed, FEMS Microbiology Reviews, mBio, Molecular Microbiology等论文。神经退行性疾病等疾病研究该方向以通讯或共通讯作者发表Autophagy, Nucleic Acids Research, Trends in Cell Biology, Biotechnology Advances, Medicinal Research Reviews, Theranostics, Molecular Neurodegeneration等论文。

英文简介

 Taking the advantage of the latest development of cutting-edge technology , Prof. Shi Chen carry out epigenetic related research, aiming to accurately identify, modify and edit the genome of cells or pathogenic bacteria, identify the defense mechanism of bacterial hosts against viruses and analyze the influence of these epigenetic modifications or genome modifications on the cell life activity or the infection ability of pathogenic bacteria. His studies in this area have published in Nature Catalysis, PNAS (2011,2017,2018), Nature Communications (2014,2019, 2022), Angew Chem Int Ed, FEMS Microbiology Reviews, mBio, Molecular Microbiology, etc. On the other hand, Prof. Chen has published in Autophagy, Nucleic Acids Research, Trends in Cell Biology, Biotechnology Advances, Medicinal Research Reviews, Theranostics, Molecular Neurodegeneration etc as his contribution in neurodegenerative disease research area.

英文名

Li Duan

联系邮箱

duanl@szu.edu.cn

中文简介

博士，研究员、副主任医师、博士生导师、深圳市第二人民医院中心实验室副主任。先后在荷兰格罗宁根大学、中山大学从事博士后研究工作，日本福冈齿科大学从事访问学者研究工作。主持国家科技部外国青年人才计划、国家自然科学基金、广东省自然科学基金重点项目和广东省国际合作项目等20项。发表SCI论文51篇，授权发明专利12项。从事纳米载药治疗骨骼肌肉系统疾病。参与的研究成果先后获得中华医学科技奖三等奖、广东省科技进步三等奖和深圳市科技进步二等奖。

英文简介

Dr Duan is a full-time researcher and vice director of Central Lab at Shenzhen Second People’s Hospital, the First Affiliated Hospital of Shenzhen University. After receiving her PhD from Wuhan University, she was a postdoctoral fellow in the Medical Center of Groningen University and Sun Yat-Sen University, then a visiting scholar in the department of Molecular Biology at the Fukuoka Dental College.

Her main research interests are the nanoparticle delivery for musculoskeletal system disease treatment. Dr Duan has received many awards such as Third prize of Chinese medical science (2017). She received many research grants, including National Natural Science Foundation of China and European Orthodontic Society. Her total research funding was more than RMB¥12,000,000. She has published 50 peer-reviewed articles, several books and book chapters.

英文名

Wenlan Liu

联系邮箱

wlliu@szu.edu.cn

中文简介

刘文兰，博士，研究员，深圳海外高层次B类人才，以诚为本赢在信誉9001cc附属第一医院/深圳市第二人民医院中心实验室主任,兼神经外科基础研究部主任。现任中华医学会神经内稳态和内分泌分会委员，中国微循环学会神经保护与康复专业委员会委员，广东省脑发育与脑病防治学会常务理事，广东省医学会实验室建设和管理学分会常务委员，深圳市医学会实验医学专业委员会主任委员。主要从事缺血性脑卒中超早期缺血半暗带和血脑屏障损伤动态演变及其与血管再通治疗后脑出血风险关系的研究，已主持完成包括美国国立卫生院、美国心脏协会、国家自然科学基金、广东省自然科学基金、深圳市科创委等科研课题25项，担任美国AHA、国家自然科学基金、广东省自然科学基金、深圳市科创委项目评审专家，已在J Neurosci、Stroke、Aging Cell、Neurobiol Dis、Exp Neurol、J Neurochem、Mol Neurobiol、Front Mol Neurosci等多个核心期刊发表SCI论文100余篇。授权美国发明专利4项，发表中国实用新型专利7项，授权中国发明专利2项。

英文简介

Liu Wenlan, MD, PhD, Professor, Shenzhen overseas high-level Class B talent, the Director of the Central Laboratory of the First Affiliated Hospital of Shenzhen University/ Shenzhen Second People's Hospital, and the Director for Basic Research of  Neurosurgery Department. Committee member of Chinese Medical Association Neural Homeostasis and Endocrine Branch, Committee member of China Society of Microcirculation Neurological Protection and Rehabilitation Committee, Standing committee member of Brain Development and Encephalopathy Prevention and Control Society, Standing committee member of Guangdong Medical Association of Laboratory Construction and Management Branch, Chair of Shenzhen Medical Association Experimental Medical Professional Committee. My research has been focused on the dynamic evolution of ischemic penumbra and blood brain barrier injury as well as their association with reperfusion therapy-associated with hemorrhagic transformation in the super-early stage of ischemic stroke. I have been a well-funded principle in the past 13 years and my research has been supported by 25 research grants from  National Health Center, American Heart Association (AHA), the National Natural Science Foundation of China, Guangdong Provincial Natural Science Foundation, and  Shenzhen Municipal Science and Technology Innovation Commission. I have served as a grant reviewer for  AHA, National Natural Science Foundation of China, Guangdong Natural Science Foundation and Shenzhen Municipal Science and Technology Innovation Commission. I have published more than 100 research papers in peer-reviewer journals including J Neurosci, Stroke, Aging Cell, Neurobiol Dis, Exp Neurol, J Neurochem, Mol Neurobiol, Front Mol Neurosci and so on. I have been authorized 4 US invention patents, 7 Chinese utility model patents, and 2 Chinese invention patents.    

英文名

LI ZESONG

联系邮箱

Lzssc@email.szu.edu.cn

中文简介

博士、研究员、博士生导师。广东省泌尿生殖肿瘤系统与合成生物学重点实验室常务副主任兼执行主任、深圳市泌尿生殖系统肿瘤研究重点实验室主任。国家重点研发计划重点专项评审专家、国家重大国际合作项目评审专家、国家自然科学基金同行评审专家。目前主要从事泌尿生殖肿瘤发生的基础及转化医学研究。先后承担国家自然科学基金面上项目3项。获授权发明专利2项。以第一完成人获国家新药证书1项。获2014年度深圳市自然科学奖一等奖1项、2014年度中华医学科技奖二等奖1项、2017年度深圳市自然科学三等奖1项、2018年广东医学科技奖一等奖1项。在包括Nature Genetics等在内的SCI杂志发表论文70篇，H指数23。

英文简介

Dr Li is currently a professor at the School of Medical Sciences, the University of Shenzhen. He graduated from the Southwest Normal University with a Bachelor of Science in biology, and obtained his Master of Science from the School of Biology of Wuhan University. Zesong Li received a Ph.D. from the School of Bioengineering of Chongqing University. After his working experience relevant to genomics of urogenital tumors with high-through sequencing in Shenzhen PKU-HKUST Medical Center, he joined the First Affiliated Hospital of Shenzhen University in 2011, where he directed his research to the molecular biology and proteomics of urogenital tumors. His research interests include marker screening and early detection of urogenital tumors by proximity barcoding assay, and identification of novel targets and signaling pathways in cancer pathogenesis and metastasis using various rodent models in vivo. Dr. Li served as the director of Shenzhen Key Laboratory of Genitourinary Tumor in 2012, and Executive Deputy Director of Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors in 2017. He has published 70 international journal articles with a majority of studies related to cancer research, including leading-authored articles in Nature genetics. He has raised a total of over 10 million Yuan in external competitive grant funding, including 3 general projects of NSFC. Moreover, he has been honored with many science and technology awards.

英文名

Xu Xundi

联系邮箱

Xuxundi@126.com

中文简介

1989年毕业于湖南医科大学医疗系英语医学专业，毕业后分配于湖南医科大学附属第二医院普外科工作,1998年赴日本京都大学医学部第二外科学习，2004年于日本大阪大学医学部第二外科获医学博士学位.从师于日本大阪大学前任副校长，日本外科学会及日本癌学会前任会长门田守人教授。擅长于肝胆胰外科疾病的诊断﹑治疗及其研究。率先开展了复杂肝门部胆管癌的根治性切除（含门静脉切除及第四型肿瘤切除术），胰腺癌的扩大根治切除等高难度复杂手术以及新技术区域动脉灌注治疗急性重症胰腺炎且取得了较好的疗效。

英文简介

He graduated from Medical Department of Hunan Medical University in 1989.After graduation,he was assigned to the General Surgery Department of the Second Affiliated Hospital of Hunan Medical University.In 1998, he went to study in the Second Surgery Department of the Medical Department of Kyoto University in Japan.In 2004, he received a medical doctor's degree in the the Medical Department of Osaka University.He learned from Professor Yu Mentian,as a former vice president and as a former president of the Japanese Surgical Society and the Japanese Cancer Society. He is good at diagnosis, treatment and research of hepatobiliary and pancreatic surgical diseases. He took the lead in carrying out highly difficult and complex operations such as radical resection of complex hilar cholangiocarcinoma (including portal vein resection and type IV tumor resection) and extended radical resection of pancreatic cancer.He has achieved good results of new technology in the treatment of acute severe pancreatitis with regional arterial infusion.

英文名

Qinghua Zhang

联系邮箱

doctorzhanghua@163.com

中文简介

医学博士、教授，主任医师、以诚为本赢在信誉9001cc博士生导师、博士后合作导师，享受“国务院特殊津贴”、深圳市地方级领军人才。华中科技大学协和深圳医院脑科中心主任、神经外科主任、学科带头人。中华医学会神经外科学分会青年委员、欧美同学会全国颅底外科分会常委等。主持国家自然科学基金2项、省部级基金项目8项、深圳市科创委重大项目1项，发表论文60余篇。获得省部级科技进步二等奖2项，三等奖1项。

擅长：人工智能与颅脑肿瘤。

英文简介

Doctor of medicine, professor, chief physician, Doctoral supervisor and postdoctoral co-supervisor of Shenzhen University, enjoy the "Special Allowance of the State Council", and Shenzhen local-level talent. Director of Brain Center, and Neurosurgery and academic leader of Union Shenzhen Hospital, Huazhong University of Science and Technology. The Youth Committee of the Neurosurgery Branch of the Chinese Medical Association, the Standing Committee of the National Skull Base Surgery Branch of the European and American Alumni Association.

Presided over two the National Natural Science Foundation, and eight the Provincial and Ministerial Fund, one major project of Shenzhen Science and Technology Innovation Commission, and published more than 60 articles, reviews and treatises. Has been the province departmental level scientific and technological progress second prize of 2, and third prize of 1.

Be good at：AI and Brain Tumors

英文名

Yingwei Qiu

联系邮箱

qiuyw1201@gmail.com

中文简介

男，医学博士，博士生导师，华中科技大学协和深圳医院放射科主任；研究方向：脑功能磁共振的临床应用，影像组学；迄今主持国家级课题两项，省部级课题三项。以第一作者或通讯作者发表学术论文40余篇，其中SCI收录36篇，包括放射科顶级杂志Radiology，NeuroImage，Human Brain Mapping，Radiotherapy and Oncology, European Radiology，AJNR，JMRI和成瘾科顶级杂志Addiction Biology等，累积影响因子160余分。

英文简介

Male, medical doctor, tutor of Ph.D.. His research focuses on functional MRI and radiomics. He had achieved 2 national scientific research project  and 3  provincial  scientific research projects. He had published more than 40 academic papers as the first author or corresponding author with IF up to 160 points, of which 36 were published in SCI periodicals such as “Radiology, NeuroImage, Human Brain Mapping, Radiotherapy and Oncology, European Radiology, AJNR, JMRI and Addiction Biology” , ect.

英文名

DiXian Luo

联系邮箱

luodixian_2@163.com

中文简介

罗迪贤，医学博士，二级研究员，博士生导师，享受国务院政府特殊津贴，湖南省杰出青年基金获得者。现任华中科技大学协和深圳医院检验医学中心主任，担任中国抗癌协会肿瘤标志专委会青委会副主任委员等多项学术任职。主要研究方向为肿瘤标志物的开发及分子机制研究、肿瘤分子诊断新技术的开发与应用等，为肿瘤早期诊断与筛查提供重要的技术支持，先后承担国家自然科学基金及省部级科研课题等十余项，发表SCI论文40余篇，出版专著6部，授权多项国家专利。

英文简介

Dixian Luo, the doctor of medicine, level-2 researcher, doctoral supervisor, the special allowance provided by the state council, and the winner of the Hunan Provincial Outstanding Youth Fund. He is currently the director of the Laboratory Medicine Center of the Union Medical College Shenzhen Hospital, Huazhong University of Science and Technology, the vice chairman of the Youth Committee of the Chinese Anti-Cancer Association Tumor Marking Special Committee. The main research direction is the development of tumor markers and molecular mechanism research, the development and application of new tumor molecular diagnosis technology, etc. He has undertaken more than ten scientific research projects for the National Natural Science Foundation of China, the provincial and ministerial levels and published more than 40 SCI research papers. Furthermore, he has authored six monographs and authorized many national patents.

英文名

HONGXIANG CHEN

联系邮箱

hongxiangchen@hotmail.com

中文简介

三级教授、主任医师、博士生导师。美国哈佛医学院麻省总医院皮肤科博士后、日本九州大学访问学者，现担任华中科技大学协和深圳医院常务副院长。

中国医师协会皮肤病、变态反应两个分会的青年副主委等学术任职10余项。主持国家自然科学基金课题6项，教育部新教师基金等10余项。2011年成为比尔及梅琳达--盖茨基金中国唯一得主（医学类项目）。发表学术论文100余篇，SCI收录60余篇。

入选 “中国皮肤科中青年优秀医师”、 “中国健康传播大使”、 “抗击新冠疫情优秀共产党员”、2021年 未来医疗100强-蔚澜奖“年度创新医院院长”等。

英文简介

Third-level professor, chief physician, and doctoral supervisor. Postdoctoral fellow in Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, and visiting scholar at Kyushu University in Japan. He is currently the executive vice president of Huazhong University of Science and Technology Union Shenzhen Hospital.

Young vice chairmen of the Dermatology and Allergy Branches of the Chinese Medical Doctor Association have held more than 10 academic positions. He presided over 6 projects of the National Natural Science Foundation of China and more than 10 projects including the New Teacher Fund of the Ministry of Education. In 2011, he became the sole winner of the Bill & Melinda-Gates Fund in China (medical projects). More than 100 academic papers have been published, and more than 60 papers have been included in SCI.

He was selected as "Outstanding Young and Middle-aged Physician in Chinese Dermatology", "Chinese Health Communication Ambassador", "Outstanding Communist Party Member in Fighting against the New Coronary Epidemic", 2021 Future Medical Top 100-Weilan Award "Annual Innovative Hospital Director", etc.

英文名

JUN WU

联系邮箱

junwupro@126.com

中文简介

现任以诚为本赢在信誉9001cc第一附属医院烧伤整形科主任，中华医学会烧伤外科分会前任主任委员、中国康复医学会烧伤治疗与康复专委会前任主委，中国医学装备协会创面修复专委会主委，国际烧伤学会前任执委会委员和东亚代表等。Burns and Trauma杂志主编（IF=5.711）、《中华烧伤与创面修复》杂志副主编。主要学术贡献：1、开创了中国烧伤康复学；2、中国烧伤界最活跃的转化医学实践者：7项专利实现转化应用；3、提升了中国烧伤界国际影响力；4、中国烧伤界慈善活动的发起人与组织者：荣获2017年度中国公益人物奖。

英文简介

Jun Wu, Professor, director of the Department of Burns and Plastic Surgery, The First Affiliated Hospital of Shenzhen University. The past president of Chinese Burn Association, the past president of Chinese Burn Rehabilitation Association, the president of Chinese Wound Repair Association, the past executive member of International Society for Burn Injury, the representative of east Asia of ISBI, etc. He is the editor-in-chief of Burns and Trauma, and the executive editor-in-chief of Chinese Burn and Wound Journal Main academic contributions: He led rehabilitation and charity processes into nation-wide Burn Units, established accreditation and certification practices, and co-created national prevention projects. He founded a world-known journal Burns and Trauma, and is active in international academic exchange. He invented low-cost biomaterial dressings that promoted Chinese burn care. Moreover, he is very active and successful in translational medicine: more than 7 patents have been transferred to investors and companies.

英文名

Hequn Zou

联系邮箱

hequnzou@hotmail.com

中文简介

邹和群，以诚为本赢在信誉9001cc附属华南医院执行院长。二级教授、主任医师、博士生导师、德国医学博士。承担国内外科研项目30余项，其中国家及国际合作科研项目10余项，课题总经费4000余万元。发表论文300余篇，其中SCI论文70余篇（JCR 1区3篇，JCR 2区 9篇）。主要研究方向：小管间质肾病发病机制及其防治；肾移植慢性失功发病机制及其防治；血液透析并发症及血浆净化临床技术研究；免疫复合物相关肾炎发病机制及其防治研究;糖尿病肾病早期诊断早期干预研究。

英文简介

Hequn Zou, Executive Dean of South China Hospital of Shenzhen University.  Professor of Nephrology, Chief Doctor, Tutor of Doctor Candidates. He has undertaken more than 30 scientific research projects at home and abroad, , including more than 10 national and international cooperative scientific research projects, with a total funding of more than 40 million yuan. More than 300 papers were published, including more than 70 SCI papers (3 in JCR Zone 1 and 9 in JCR Zone 2). Main research directions: Pathogenesis and prevention of tubulointerstitial nephropathy,Pathogenesis and prevention of chronic renal allograft failure, Study on complications of hemodialysis and clinical techniques of plasma purification, Study on the pathogenesis, prevention and treatment of immune complex associated glomerulonephritis, Early diagnosis and early intervention of diabetic nephropathy.

英文名

Qiwen Deng

联系邮箱

qiwendeng@hotmail.com

中文简介

邓启文，医学博士，主任医师，华中科技大学协和深圳医院院长，感染科学科带头人，深圳市科技创新委内源性感染诊治研究重点实验室主任，以诚为本赢在信誉9001cc博士生导师、博士后合作导师。在11个国家、省市级微生态及感染相关学会任职，获得国家级、省级等各类课题资助15项，金额达四百多万。发表SCI文章50余篇，获得相关专利5项。长期从事感染疾病的诊疗和医院感染防控工作，是疑难危重感染疾病诊疗、院感防控以及抗微生物感染研究等方面的国内知名专家。目前主要的研究方向：①细菌病原体感染的无创诊断和治疗新技术；②抗感染新药的筛选鉴定、递送及机制研究；③微生物耐药及发病机理研究；④微生态与疾病相互关系研究。

英文简介

Deng Qiwen, M.D., Chief Physician, President of Huazhong University of Science and Technology Union Shenzhen Hospital, Leader of the Department of Infectious Diseases, Director of the Key Laboratory of Endogenous Infection Diagnosis and Treatment of the Shenzhen Science and Technology Innovation Commission, Ph.D. supervisor and Postdoc advisor of Shenzhen University. He has served in 11 national, provincial, and municipal microecology and infection-related professional societies, and has received 15 national and provincial grants with a funding amount of over 4 million RMB. More than 50 SCI articles and 5 related patents were published and obtained. Dr. Deng has long been engaged in the diagnosis and treatment of infectious diseases and the prevention and control of hospital infections and is a well-known domestic expert in the diagnosis and treatment of difficult and critical infectious diseases, the prevention and control of hospital infections, and the research of antimicrobial infections. His current research interests include (1) new technologies for non-invasive diagnosis and treatment of bacterial pathogenic infections; (2) screening, identification  and delivery of new anti-infective drugs and their mechanisms; (3) research on microbial drug resistance and pathogenesis; (4) research on the interrelationship between microecology and disease.

英文名

Fu Li

联系邮箱

gracelfu@szu.edu.cn

中文简介

付利，肿瘤遗传学博士，教授，深圳市海外高层次人才，鹏城学者，博士生导师，以诚为本赢在信誉9001cc优秀学者，基础医学院副院长。长期致力于消化道恶性肿瘤新型诊疗靶点的发掘及创新药物研究。近5年来主持承担科研项目10余项，其中包括国家自然科学基金面上项目、国家重大研发计划重点专项子课题、深圳市科创委基础研究重点项目、香港政府研究资助局GRF/CRF项目等。申报国家发明专利8项，已获授权6项。在国际主流杂志发表SCI学术论文88篇，其中Gut、 Hepatology、PNAS、Cancer Research、Clinical Cancer Research等通讯或第一作者论文36篇。他引3500余次，H指数37。

英文简介

Personal Statement (ORCID 0000-0003-2643-6278):

My research goal is to understand the mechanisms of initiation and progression of gastrointestinal (GI) cancers and identify new therapeutic targets for cancer treatment. 

The research in my laboratory has been continuously supported by the National Natural Science Foundation in China (NSFC), General Research Fund (GRF) of Hong Kong, and grants from the Shenzhen Science and Technology Innovation Department since 2014.  I have published 88 papers in the cancer research field in various peer-reviewed international journals (H-Index 37), including Gut, Hepatology, PNAS, Cancer Research. I have obtained 6 China patents and have been awarded the Overseas High-level Talents and Pengcheng Scholar Distinguish Professorship by the Shenzhen Government. I am currently mentoring one postdoctoral fellow, two PhD and five MSc candidates.

Research Interests:

•Prognostic and predictive tumor biomarker discovery and development;

•Molecular mechanism of the immunosuppressive tumor microenvironment;                                                                       

•Tumor stroma and cancer stem cell-targeted novel immunotherapeutic strategies.

英文名

Huangcibo

联系邮箱

Huangcibo1208@139.com

中文简介

黄慈波，男，风湿免疫学硕士，主任医师，博导，二级教授,以诚为本赢在信誉9001cc附属华南医院副院长，中华医学会内科学分会候任主委。主要从事风湿免疫病学基础与临床研究，包括骨关节炎、干燥综合征和免疫吸附技术治疗风湿免疫疾病的基础研究、系统性硬皮病、系统性血管炎、红斑狼疮和类风湿关节炎等基础与临床研究。主要科研方向:免疫净化技术治疗免疫相关性疾病及吸附柱研发;骨关节炎发病机制及干细胞转化软骨细胞关节注射研究;EDTA治疗各种纤维化疾病;老年多脏器疾病用药指导与多脏器衰竭的诊治;生物制剂治疗关节炎和自身免疫性疾病。

英文简介

Professor Cibo Huang, master of rheumatology and immunology, chief physician, doctoral supervisor, grade II professor, vice president of South China Hospital, Shenzhen University, and Chairman-designate of Internal Medicine Branch of Chinese Medical Association. He is mainly engaged in basic and clinical research in rheumatology, including basic research on osteoarthritis, Sjogren syndrome and immunosorbent technology for rheumatic immune diseases such as systemic scleroderma, systemic vasculitis, lupus erythematosus and rheumatoid arthritis. His main research interests include: immunopurification technology for immune-related diseases and development of immunosorbent column; research on the pathogenesis of osteoarthritis and intra-articular injection of chondrocytes transformed from stem cells; research on EDTA treatment for various fibrotic diseases; research on medication guidance for geriatric multi-organ diseases and diagnosis and treatment of multi-organ failure; research on biological agents treatment for arthritis and autoimmune diseases.

英文名

Huang Weiren

联系邮箱

pony8980@163.com

中文简介

以诚为本赢在信誉9001cc第一附属医院（深圳市第二人民医院转化医学院副院长，泌尿外科教授。国家重点研发计划项目首席科学家。广东省泌尿生殖肿瘤系统与合成生物学重点实验室副主任，深圳市医学基因重编程技术重点实验室主任。主要从事肿瘤精准医学及合成生物学研究。所在团队近年来以国内高发的膀胱癌为模型较早将工程化理念与肿瘤研究结合，系统的发掘出一批膀胱癌细胞表型识别和控制有效靶点；完成了膀胱癌特异基因开关元件的合成和表征；构建出可同时感应多层面信号的人工基因线路，实现肿瘤细胞的特异区分和肿瘤信号网络的智能识别与人工调控，进一步深入理解肿瘤发病机理。建立上尿路上皮癌、膀胱癌、肾癌、前列腺癌、肺癌、甲状腺癌等超10个癌种的类器官培养方法，并开展相关药物筛选及评估研究，部分癌种为全球首次报道，并在肿瘤精准医学与药物研发方面开展了多种应用探索。在Nature Methods、Nature Communications、Advance science、Genome Biology等刊物发表学术论文100多篇，获授权国家发明专利14项，获中华医学奖1项（第一完成人），深圳市自然科学奖1项（第一完成人）。

英文简介

Professor of urology and Vice President of Translational Medical College, The First Affiliated Hospital of Shenzhen University. Chief scientist of the National Key R&D Program. Deputy Director of Guangdong Key Laboratory of Urogenital Neoplasms and Synthetic Biology, Director of Shenzhen Key Laboratory of Medical Gene Reprogramming Technology. Dr. Huang is mainly engaged in the research of precision medicine and synthetic biology in cancer. In recent years, Professor Huang's team took the high incidence of bladder cancer in China as a model to combine the engineering concept with tumor research early, and systematically discovered a number of effective targets for phenotype recognition and control of bladder cancer cells. The synthesis and characterization of bladder cancer specific gene switch elements were completed. An artificial gene circuit that can simultaneously sense multilevel signals is constructed to realize the specific differentiation of tumor cells and the intelligent recognition and artificial regulation of tumor signal network, and further understand the pathogenesis of tumor. Organoid culture methods were established for more than 10 cancer species, including upper urothelial cancer, bladder cancer, kidney cancer, prostate cancer, lung cancer and thyroid cancer, and related drug screening and evaluation studies were carried out. Some cancer species were reported for the first time in the world, and a variety of application exploration was carried out in tumor precision medicine and drug research and development. He has published more than 100 academic papers in journals such as Nature Methods, Nature Communications, Advance science, Genome Biology, etc. He has been granted 14 national invention patents and won the Chinese Medicine Award (First Accomplisher). Shenzhen Natural Science Award (First Accomplisher).

英文名

Yuyang Jiang

联系邮箱

jiangyy@sz.tsinghua.edu.cn

中文简介

男，博士，教授，973首席科学家，国家863海洋专家组成员，深圳市国家级领军人才。省部共建肿瘤化学基因组学国家重点实验室常务副主任，广东省化学生物学重点实验室主任。研究方向为肿瘤的化学生物学，研究内容包括肿瘤的作用机制和信号传导网络、多靶点药物的设计与合成、肿瘤的特异性识别检测、代谢组学研究、蛋白质组学研究等。承担了科技部863专题、973计划、国家重大专项、国家自然科学基金、国际科技合作以及其它国家、省市级科研项目。在国际著名学术期刊Nature Biotechnology、Proceedings of the National Academy of Sciences of the United States of America上发表SCI科研论文300余篇，申请专利68项，其中授权专利42项。

英文简介

Deputy director of State Key Laboratory of Chemical Oncogenomics. Director of Guangdong Province Key Laboratory of Chemical Biology.

Research Fields:

1. The design, synthesis and bioactivity study on small molecular inhibitors targeting tumor-related pathways.

2. Signal pathways and networks in tumor cells regulated by pokemon, and biomarker discovery.

3. Metabolic and proteomics study on tumor and pharmaceutical analysis.

4. Chemical modification of nucleosides and its application in antitumor gene drugs.

5. Fluorescence-based biosensors and molecular probes targeting cancer diagnosis and drug mechanism studies.

英文名

Weihua Li

联系邮箱

18804511716@163.com

中文简介

教授，博士生导师，美国临床医学博士，肿瘤分子影像领域专家学者。曾工作于美国国立卫生研究院（NIH）（世界最具影响力，美国最高水平国家研究机构），生物工程与医学成像分子成像与纳米医学中心（NIBIB）。全球知名大学、医院临床工作访问。担任大学、本科生研究生推荐教材编委，编译专业论著，参与完成国际合作，国家顶级科研项目十余项，发表研究论著数十篇，是多个英文杂志的审稿人。担任世界分子影像协会会员 (WMIS)  北美放射协会会员 (RSNA)  美国分子影像学会会员 (AMI)  美国核医学与分子影像学会会员（SNMMI），分别在2011、2016、2017年度的“国际WMIC大会”“国际HIVR4P大会＂上获奖。

主要研究领域：新型分子影像造影剂开发；用于多重生物标志物检测的超灵敏方法；构建智能纳米平台用于药物和基因的靶向递送；分子影像探针的临床转化；诊疗一体化纳米材料开发及临床转化。

英文简介

  Professor, doctoral supervisor, American clinical medical doctor, expert and scholar in the field of tumor molecular imaging. Prof. Li has worked at National Institutes of Health (NIH) (the most influential national research institutions in the world), National Institute of Biomedical Imaging and Bioengineering (NIBIB). Dr. Li had clinical work visits to world-renowned universities and hospitals. She had been on the editorial board of recommended textbooks for universities and graduate students, compiled professional works, participated in international cooperation and completed more than ten national top scientific research projects. She has published tens of research works, and is a reviewer of many English magazines. And she is the member of the World Molecular Imaging Congress (WMIS) and Radiological Society of North America (RSNA). In 2011, 2016 and 2017, she won prizes at WMIC and HIVR4P.

Main research areas: development of novel molecular imaging contrast agents; ultra-sensitive method for detection of multiple biomarkers; building smart nano-platforms for targeted delivery of drugs and genes; clinical transformation of molecular imaging probe; development and clinical transformation of nanomaterials integrated with diagnosis and treatment.

英文名

Nan Liu

联系邮箱

13688869875@163.com

中文简介

刘 楠， 男，42岁，汉族，博士，PI，以诚为本赢在信誉9001cc博士生导师，河南省学位委员会第四届学科评议组成员，入选广东省、湖北省、江苏省和河南省的高层次人才评审、创新项目评审专家库。从事环境与健康领域的科学研究已经有20年，致力于环境与健康风险因子监控与评估、风险评估关键技术研究（生物芯片、生物传感与POCT）、生物活性物质的营养学评价与功能开发研究、快速检测技术研究和相关装备的研发、环境污染物分子作用机制科学研究、科技项目组织管理等。2008-2009年曾借调于国家科技部，主管国家食品安全项目，国家863计划青年科学家课题获得者和中国毒理学会青年科技奖获得者。目前担任中国研究型医院学会医工转化与健康产业融合发展专业委员会常委、中华医学会航海医学分会专业委员会常务委员、广东省护士协会第二届理事会临床护理研究分会副会长、中国妇幼保健委员会家庭保健委员会委员、中国仪器仪表学会环境与安全检测仪器分会理事、中华医学会卫生检验学专委会委员、全国“打非添”专项整治专家委员会成员、天津市生物医学工程学会青年工作委员会委员、《中华预防医学杂志》通讯编委、多种国际期刊审稿人等。主持承担国家863计划项目、国家自然科学基金项目、军队、部委等课题10多项，发表学术文章80多篇（SCI第一及责任通讯作者40篇，总IF>120）；获得授权专利15项；参与国家军用标准制修订4项。出版专著十余部(副主编1部，参编英文专著2部，国内专著10余部)。

英文简介

Prof/Dr. Nan Liu, M. D., received doctorate degree from Academy of Military Medical Science, Beijing, China in 2009, mainly engaged in the development of environment and health. He has served the army for almost 15 years in 2003-2017. Now, he is in charge of Department of Science and Education and Institute of Environment and Health in South China Hospital, Shenzhen University.

His research areas are including: molecular network regulation mechanism of chronic injury induced by combined exposure of environmental pollutants, key technologies for monitoring and assessment of environmental and health risk factors and rapid determination of chemical pollutants, etc. He has published 80 papers including 40 with the first/corresponding authorship and taken charge of a variety of the Natural Science Foundation of China (4 items), the National High Technology Research and Development Program of China.

He has rewarded the Youth of Science and Technology Award of Chinese Society of Toxicology in China and the first "Innovation Strategic Talent Project" talents in Academy of Military Medical Sciences.

英文名

XIN-HAI PEI

联系邮箱

peixinhai@szu.edu.cn

中文简介

以诚为本赢在信誉9001cc特聘教授，解剖组胚系主任, 动物中心主任，曾任美国北卡罗来纳大学助理教授，迈阿密大学终身轨副教授，独立PI。主要采用基因工程小鼠研究细胞增殖和分化在人类疾病中的作用与机制。已建立自主制备基因工程小鼠，复杂动物手术及分子病理分析等特色平台。制备和鉴定了45种不同品系基因敲除小鼠，拥有多种基因敲除小鼠疾病模型。首次证明Cul9和p19为抑癌基因，p18受GATA3调控, BRCA1抑制三阴乳腺癌转移。现主持3项国家及省市科研项目。曾主持13项270余万美元美国联邦和大学科研项目。 2010和2013两次美国DOD乳腺癌研究新想法奖获得者。发表SCI论文44篇。

英文简介

Dr. Pei is interested in using mouse genetic approaches to investigating the molecular and cellular basis of tumor suppression. Though time consuming and complicated, utilizing such methodology is a necessary step toward the goal. Dr. Pei generated 5 strains of knockout mice and characterized 45 different mouse mutants for various cell cycle inhibitors and tumor suppressors, and demonstrated their functions in the control of stem/progenitor cells and tumorigenesis of multiple tissues. Dr. Pei discovered that p18^INK4c is a downstream target of GATA3 and restrains mammary luminal progenitor proliferation and tumorigenesis (Pei XH, Cancer Cell, 2009).  As a tenure track assistant and associate professor at the University of Miami, Dr. Pei published 17 research papers. He discovered that deletion of Brca1 causes luminal-to-basal mammary tumor transformation (Bai F, Oncogene, 2013). BRCA1 suppresses EMT during mammary and tumor development (Bai F, Cancer Res., 2014). Since Oct 2018, Dr. Pei has been moving to China and working as a full professor at the Shenzhen University School of Basic Medical Sciences. In addition to the abovementioned areas, he is also very interested in 1) how LncRNA controls cancer development and progression; 2) how cell cycle inhibitors and transcription factors control cochlea hair cells in hearing loss and tubular cells in polycystic kidney disease. Recently, he discovered that loss of function of BRCA1 promotes EMT in mammary tumors through activation of TGFβR2 signaling pathway (Cell Death & Disease, 2022) and loss of function of GATA3 induces basal-like mammary tumors (Theranostics, 2022).

英文名

Wen Su

联系邮箱

suwen@szu.edu.cn

中文简介

  苏文博士的研究方向长期聚焦于“脂滴及脂滴蛋白在脂代谢和代谢性疾病中的作用及机制研究”。她纯化并建立了人肝脏脂滴相关蛋白谱，并确认了一系列在人非酒精性脂肪性肝病（NAFLD）中变化的脂滴相关蛋白。她确认其中一个肝脏特异性脂滴蛋白17β-HSD13是NALFD发病的致病因子(2014, 111 (31):11437, PNAS)。从她加入深大后，她开展了一系列相关研究，包括：(1) 利用多种基因工程小鼠展开17β-HSD13的功能学研究; (2) 阐明急性和慢性肝损伤中脂代谢紊乱的机制; (3)筛选17β-HSD13，FXR,LXR为靶点的脂肪肝治疗药物. 苏文博士的原创性研究为脂肪肝治疗提供了新的潜在靶点并被新英格兰杂志在大规模人群上验证。她发现体内、外过表达17β-HSD13均能增加脂滴的大小和蓄积，其机制是通过调控SREBP-1c的成熟。苏文博士目前已有发明专利2项，构建了多种转基因工程小鼠。她接下来的五年研究计划为1.确认多种基因工程小鼠的代谢表型；2. 结合多种NASH（脂肪性肝炎）动物模型明确17β-HSD13在NAFLD整个发病过程中的作用； 3. 利用生化、脂质组、代谢组手段明确17β-HSD13的细胞生理学功能；4. 在细胞侧面研究17β-HSD13在脂滴新生、成熟、融合和降解及翻译后修饰过程中的精确调控机制，苏文博士目前H-index指数为17。

英文简介

Dr.Su has been focusing on the field “lipid droplet, lipid droplet proteins, dysregulation of lipid metabolism and metabolic diseases” for a long time with a series work. She purified and established human liver LD-associated proteome and identified an array of proteins differentially expressed in human NALFD. She demonstrated a liver-specific LD protein 17βHSD13 as a pathogenic factor and drug target of NAFLD (2014, 111 (31):11437, PNAS). Since joining Shenzhen University, she carried out several related studies, including: (1) Function study of 17β-HSD13 by using various hsd17b13 (the gene codes 17β-HSD13) genetic edited mice and biochemistry methods; (2) Elucidate the mechanism of lipid dysregulation in acute and chronic liver diseases; (3) Screen of lead compounds that targets 17β-HSD13, FXR, LXR for NAFLD treatment. Dr Su’s original research about 17β-HSD13 provides a potential link between LD proteins and NAFLD, and has been cited by more than 120 papers including papers on NEJM, hepatology, journal of hepatology and so on. She found over-expression of 17β-HSD13 in vivo and in vitro increases size and accumulation of lipid droplets in hepatocytes, which possible mechanism is through enhancement of lipogenesis and maturation of SREBP-1c. Her subsequent work demonstrated 17β-HSD13 was regulated by LXRα agonist T0901317 via a SREBP-1c dependent mechanism (2017, 312(4), Am J Physiol Endocrinol Metab.;2018, 67(supplement 1), Diabetes). She proposed the possible regulation mechanism of 17β-HSD13 and SREBP-1c, and suggested 17β-HSD13 as a potent NASH target (2019, 489:119-125, Mol Cell Enocrinol.). She has 2 patents on 17β-HSD13 and NAFLD drug target. She now successfully constructed 17β-HSD13 liverspecific transgenic, knockout, liver-specific knockout, and two key amino site mutant mice lines, and also a various of HSD17B13 associated plasmid. Her next 5 year-plan include: 1. Define the metabolic phenotypes of those genetically engineered mice; 2. Determine the pathophysiological role of 17βHSD13 during different stages of NAFLD from benign steatosis, NASH to HCC via challenging highfat diet (short term and long term), MCD, and FPC models; 3. Characterize the biological function of 17β-HSD13 by using biochemical, lipidomic, and metabolomic approaches; 4. Study the role 17β-HSD13 in regulating LD generation, growth, fuse, and degradation and the post-translational modification of 17βHSD13. In terms of paper publication and academic effect. Dr.Su’s h-index is 17.

英文名

Lei Wang

联系邮箱

Lei.wang@szu.edu.cn

中文简介

香港科技大学本科与硕士学位，美国加州大学河滨分校博士学位，美国希望之城(City of Hope)国家医学中心博士后。研究方向长期聚焦肿瘤免疫学, 与临床医生紧密合作，运用单细胞多组学、超多色免疫荧光和高参数流式细胞术等技术，结合生物信息学，探究肿瘤发生发展对患者全身性免疫系统的影响作用，揭示免疫疗效机理机制，并寻找免疫治疗标志物。近年来以第一作者在Nature Immunology等国际刊物共发表学术论文10余篇，现主持国自然面上项目等科研项目。

英文简介

The focus of my research is on exploring how immunotherapy impacts the dynamic of immune responses in patients with solid tumors, with the goal of understanding the immunoregulatory mechanisms of host systemic immunity and developing novel prognostic/predictive biomarkers. We utilize state-of-the-art technologies – such as single-cell multiomics, quantitative spatial image analysis, high-parameter flow cytometry and advancebioinformatics – to dissect the complex interplay between immune cells and cancer cells within tumor microenvironment and host immune macroenvironment including tumor-draining lymph nodes and peripheral blood.

英文名

nixie

联系邮箱

xn100@szu.edu.cn

中文简介

谢妮，肿瘤学、管理学博士、研究员、博士生导师、教授，长期从事肿瘤发生发展、复发转移以及耐药的分子机制研究。现任深圳市第二人民医院科教科科长、生物样本库主任，广东医科大学博士生导师，以诚为本赢在信誉9001cc、广州医科大学、南华大学硕士生导师。中国研究型医院学会临床数据与样本资源库专业委员会信息组委员、中国研究型医院学会临床数据与样本资源库专业委员会委员、中国研究型医院学会病毒肿瘤学专委会常委、中国抗癌协会肿瘤标志物委员会委员、广东省医学会精准医学与分子诊断学分会常务委员、广东省中医药学会中西医交融专业委员会常务委员、广东省自然科学基金同行评审专家、深圳市科技评审专家、深圳市免疫细胞治疗工程实验室主任、深圳市纳米酶肿瘤转化医学重点实验室副主任。担任《Cancer Management and Research》、《国际肿瘤前沿杂志》编委。近年来发表国内外核心期刊50余篇，其中包括Nat. Commun、Theranostics等国际著名刊物SCI文章33篇，获得国家发明专利6项。主持国家级、省市级项目17项，近5年获得项目经费2000余万元，培养硕士研究生15名，获得中国中西医结合学会科学技术二等奖一项，广东省科技进步奖二项。

英文简介

Ni Xie, doctor of oncology and management, researcher, doctoral supervisor, professor, has been engaged in the molecular mechanism research of tumor development, recurrence, metastasis and drug resistance for a long time. At present, she is the chief of science and education department and director of biobank of Shenzhen Second People's Hospital, doctoral supervisor of Guangdong Medical University, master supervisor of Shenzhen University, Guangzhou Medical University and Nanhua University.

Member of the information group of the professional committee of clinical data and sample resource base of China Research Hospital Association, member of the professional committee of clinical data and sample resource base of China Research Hospital Association, member of the Standing Committee of the special committee of viral oncology of China Research Hospital Association, member of the tumor marker Committee of China Anti-Cancer Association, and standing member of the precision medicine and molecular diagnostics branch of Guangdong Medical Association Standing member of the professional committee of integration of Chinese and Western medicine of Guangdong Academy of traditional Chinese Medicine. Guangdong Provincial Natural Science Foundation peer review expert, Shenzhen Science and technology review expert, director of Shenzhen immune cell therapy Engineering Laboratory, deputy director of Shenzhen Key Laboratory of nanoenzyme oncology.

She serves as the editorial board member of "Cancer Management and Research" and "International Journal of Oncology". She published more than 40 high-quality academic papers in international journals such as Nat. Commun, Theranostics, and Obtained 6 national invention patents. She has presided over more than 20 national, provincial and municipal projects. In the past 5 years, she has received more than 20 million yuan in project funding, trained 15 postgraduates, won the second prize of science and technology of the Chinese Society of Integrated Chinese and Western Medicine, and won the Guangdong Science and Technology Progress Award.

英文名

Liang Ye

联系邮箱

liangyeszu@163.com

中文简介

叶亮，以诚为本赢在信誉9001cc医学部副教授，卡尔森国际肿瘤中心独立PI。“珠江人才计划”青年拔尖人才、深圳市海外高层“孔雀计划”B类人才。以第一作者或通讯作者身份在Nat. Immunol、Nat. Rev. Immunol、J. Virol、J. Immunol、Theranostics等期刊发表论文，成果被Nature Immunology、eLife 期刊发表重点专题点评。课题组长期从事病毒感染与宿主免疫机制研究。利用多种基因缺陷小鼠和条件性敲除小鼠构建病毒感染动物模型，重点探究干扰素系统抗病毒感染的免疫调控机理，从表观遗传修饰角度解析病毒逃逸宿主免疫和入侵宿主的作用机理，开发新型病毒疫苗与纳米中和抗体，为遏制病毒感染性疾病的诊断、预防和治疗提供新策略。

英文简介

Liang Ye, Associate professor and independent PI of Shenzhen University Health Science Center. "Pearl River Talent Program" young top talents, Shenzhen overseas high-level "Peacock Program" category B talents. Our findings have been published in Nat. Immunol, Nat. Rev. Immunol, J. Virol, J. Immunol, Theranostics, and other journals, and have been widely cited by Nature Immunology and eLife journals. Our group was interested in the immunoregulatory mechanism of host defense against viral infection. We developed a variety of gene-deficient mice and conditional knockout mice to investigate the immunoregulatory mechanism of the interferon system (type I and type III IFNs) against viral infection, the effects of epigenetic modification on virus invasion and escapism host immunity, and the exploration of new viral vaccines and neutralizing nanobodies to combat viral infectious diseases.

英文名

Zhijian Yu

联系邮箱

yuzhijiansmu@163.com；

中文简介

余治健，主任医师，医学博士，以诚为本赢在信誉9001cc博士研究生导师，华中科技大学协和深圳医院感染科主任。长期从事感染疾病的诊疗和医院感染防控工作，在新发传染病和疑难发热性疾病领域具有丰富的临床经验。2019年至今发表国际性SCI收录论文23篇（第一或者通讯作者），其中15篇影响因子大于5，2影响因子>10。共获得13项国家级省级等基金项目资助，约400万元人民币。此外，在7个国家、省市级微生态及感染相关学会任职。研究方向为①抗感染药物的筛选鉴定、优化改进、递送及相关机制研究；②生物被膜形成的分子机制；③细菌耐药机制及抗生素耐药演化特征研究；④院感控制新方法开发；⑤运用蛋白质组、代谢组等多组学相关技术对药物抗菌机制进行研究。

英文简介

Dr. Yu Zhijian, Chief Physician, Doctor of Medicine, Ph.D. supervisor of Shenzhen University, Chief Physician, Director of the Key Laboratory of Nosocomial Infection, Director of the Department of Infectious Diseases of Huazhong University of Science and Technology Union Shenzhen Hospital. He has long been engaged in the diagnosis and treatment of infectious diseases and hospital infection prevention and control and has extensive clinical experience in the field of emerging infectious diseases and difficult febrile diseases. Since 2019, 23 international SCI papers (first or corresponding author) have been published, of which 15 have impact factor >5 and 2 >10. He has received 13 national, provincial and other grants with about 4 million RMB. In addition, he has served in 7 national, provincial and municipal microecology and infection-related societies. His research interests include (1) the screening, identification, optimization and delivery of anti-infective drugs and their mechanisms; (2) molecular mechanisms of biofilm development; (3) study of bacterial resistance mechanisms and evolutionary characteristics of antibiotic resistance; (4) development of novel approaches for nosocomial infection control; (5) applying proteomics and metabolomics and other related multi-omics technologies to help study the antibacterial mechanism of drugs.

英文名

Li-bin Wang

联系邮箱

Wanglibin007@126.com

中文简介

王立斌，研究员，美国MD安德森肿瘤中心访问学者。主持各类科研项目10余项，累计科研经费1000余万元。申报发明专利28项， 获批4项，出版学术专著3本；发表科研论文60余篇。主要研究方向：

1. 肿瘤增殖转移耐药的分子调控机制研究：研究肿瘤干细胞在肿瘤发生和耐药过程中的分子调控机制，肿瘤干细胞特异基因表达的分子调控网络；开发针对肿瘤干细胞特异基因的靶向治疗技术方法。

2. 间充质干细胞基础和临床应用研究：研究间充质干细胞免疫原性及其在疾病临床治疗中的作用机制；开展间充质干细胞及其外泌体在疾病靶向治疗中的临床转化。

英文简介

Dr. Li-bin Wang was once a visiting scholar at MD Anderson Cancer Center in the United States. He has presided more than 10 research projects, with a total research funding of more than 10 million yuan. He has declared 28 invention patents, 4 of which have been authorized. He has published more than 60 scientific research papers. Dr. Li-bin Wang's research focuses on two area:

1. Molecular regulatory mechanisms of drug resistance in tumor proliferation and metastasis; The aim of the research was to study the molecular mechanism of tumor stem cells in the process of tumorigenesis and drug resistance, and to develop the molecular network of tumor stem cell. To find a targeted therapy technology for tumor stem cell.

2. Mesenchymal stem cells immunogenicity and its clinical application; The aim of the research was to study the immunogenicity of mesenchymal stem cells and their mechanism in the clinical treatment of diseases. To carry out clinical translational of mesenchymal stem cells and their exosomes in the targeted treatment of diseases.

英文名

Changyu Jiang

联系邮箱

jiang-changyu@hotmail.com

中文简介

在日本获得医学博士学位，在美国杜克大学从事博士后研究工作。主要研究方向为神经病理性疼痛的神经免疫机制，以及多肽，神经调控的镇痛作用和机制研究。近年来相继在Nature，Neuron，Science translational medicine等高水平国际期刊发表近60篇学术论文，并获得国家自然科学基金面上项目、广东省自然科学基金，深圳市重点项目等课题共7项。

英文简介

Dr. Jiang obtained his doctorate in medicine in Japan and is engaged in postdoctoral research at Duke University. He mainly focus on the immune-neuronal mechanisms of neuropathic pain, as well as on the analgesic effects and mechanisms of peptides and neuromodulation. In recent years, he has published nearly 60 academic papers in high-level international journals such as Nature, Neuron, and Science translational medicine. His group has been supported by National Natural Science Foundation in China, Basic Research Foundation of Guangdong, the Key Research Founda

英文名

Yonghui Li

联系邮箱

yonghuililab@163.com

中文简介

博士、研究员，广东省“珠江人才计划”领军人才，以诚为本赢在信誉9001cc总医院中心实验室主任、深圳市恶性血液病精准诊疗重点实验室副主任，现任中国研究型医院学会血液病精准诊疗专业委员会副主任委员。国际知名杂志Oncogene、FASEB、FEBS J特约审稿专家和国家自然科学基金评审专家，教育部学位评审专家。

主要研究方向：急性髓系白血病发生的遗传学与表观遗传学机制、表观遗传学与恶性肿瘤早期的克隆演变，m6A甲基化与基因组稳定性等。

主持国家自然科学基金面上项目共8项。近年来以第一作者或通讯作者在Blood、EMBO Mol Med、Biosens & Bioelectron、FASEB J、Int J Cancer等国际杂志发表SCI论文七十余篇。

英文简介

Dr. Yonghui Li: Professor, honored of Leading talent of Guangdong “Pearl River Talents Program”, Director of Central Laboratory of Shenzhen University General Hospital, Deputy Director of Shenzhen Key Laboratory of Precision Medicine for hematological Malignancies, Vice-chairman of the committee of hematology precise diagnosis and treatment of China Research Hospital Association. Special review expert for international famous magazine Oncogene、FASEB、FEBS J and the National Natural Science Fund Review Expert, the Ministry of Education Degree Review Expert.

Research interests：1, Genetic and Epigenetics mechanisms of acute myeloid leukemia; 2, Epigenetics in Clonal evolution of malignant tumors; 3, m6A methylation and genome stability. Presided over a total of 8 projects from the National Natural Science Foundation of China. In recent years, more than 70 SCI papers have been published in Blood, EMBO Mol Med, Biosens & Bioelectron, FASEB J, Int j Cancer, etc. .

英文名

Qin Wang

联系邮箱

wangqinmail@126.com

中文简介

医学博士，副主任医师，硕士生导师，博士后导师。在国内外杂志上发表科研论文共20余篇，最高为PNAS杂志。主持国自然面上项目1项，青年项目1项。主要研究方向：肾脏与高血压的关键分子及相关机制研究、慢性肾脏病钙磷代谢机制及干预研究。

英文简介

Qin Wang, M.D., Ph.D., Associate Professor.

Professor Wang has published more than 20 papers (including PNAS) and was awarded several times because of the excellent findings including New Investigator Award from AHA/ASH(2018), JSH/SHR award(2018), Asian session Runner-up Poster Award from JSN (2019). As a chief investigator, she was granted by Chinese National Natural Science Foundation for young investigator project in 2019, and a general program in 2022.Her project focused on key molecular mechanisms involved in hypertensive kidney diseases and Calcium-phosphate metabolism in chronic kidney disease.

英文名

Liang Ye

联系邮箱

liangyeszu@163.com

中文简介

叶亮，以诚为本赢在信誉9001cc医学部副教授，特聘研究员，卡尔森国际肿瘤中心独立PI。“珠江人才计划”青年拔尖人才、深圳市海外高层“孔雀计划”B类人才。以第一作者或通讯作者身份在Nat. Immunol、Nat. Rev. Immunol、J. Virol.、J. Immunol.、Theranostics等期刊发表论文，成果被Nature Immunology、eLife 期刊发表重点专题点评。课题组长期从事病毒感染与宿主免疫机制研究。利用多种基因缺陷小鼠和条件性敲除小鼠构建病毒感染动物模型，重点探究干扰素系统抗病毒感染的免疫调控机理，从表观遗传修饰角度解析病毒逃逸宿主免疫和入侵宿主的作用机理，开发新型病毒疫苗与纳米中和抗体，为遏制病毒感染性疾病的诊断、预防和治疗提供新策略。

英文简介

Liang Ye is an associate professor, distinguished researcher, and independent PI of the Shenzhen University Health Science Center. "Pearl River Talent Program" young top talents, Shenzhen overseas high-level "Peacock Program" category B talents. Our findings have been published in Nat. Immunol, Nat. Rev. Immunol, J. Virol., J. Immunol., Theranostics, and other journals and have been widely cited by Nature Immunology and eLife journals. Our group was interested in the immunoregulatory mechanism of host defense against viral infection. We developed a variety of gene-deficient mice and conditional knockout mice to investigate the immunoregulatory mechanism of the interferon system (type I and type III IFNs) against viral infection, the effects of epigenetic modification on virus invasion and escapism host immunity, and the exploration of new viral vaccines and neutralizing nanobodies to combat viral infectious diseases.

英文名

Xiangyu Liu

联系邮箱

liuxiangyu@szu.edu.cn

中文简介

北京大学医学部八年制本博连读，哥伦比亚大学医学院博士后及副研究科学家，以诚为本赢在信誉9001cc特聘研究员，基础医学院生物化学与分子生物学副主任。深圳市孔雀人才。中国抗癌协会肿瘤病因学专业委员会会员，中国生物化学与分子生物学学会基因专委会委员，中国细胞生物学学会会员，深圳市生物化学与分子生物学会理事。主要从事DNA损伤修复机制与癌症发生发展机制相关方面的研究。主要应用分子生物学，遗传学，实验动物学等方法。主持国家自然科学基金委面上项目2项。

英文简介

Our long-term goal is to use molecular and genetic approach to understand the relationships among different DNA repair pathways and how they coordinate to maintain genome stability and prevent human diseases such as ageing and cancer. In general, I am interested in how cells respond to different DNA damaging stress (such as nuclease mediated cutting, topoisomerase inhibitors, irradiation or radiomimetic drugs, etc) and how different repair pathways determine the final fate of the cells. In particular, in the next few years, I expect to continue my study firstly on 53BP1 and CtIP and their functional interactions with other DNA damage response proteins to explore the mechanism of DNA repair in the face of different kinds of DNA damage. In the long run, I plan to extend my research looking for new and novel factors from human patients that play vital roles in DNA repair and tumorigenesis.

Website: https://med.szu.edu.cn/Item/2395.aspx

英文名

Liu Qi

联系邮箱

Liu_qi@szu.edu.cn

中文简介

以诚为本赢在信誉9001cc医学部卡尔森国际肿瘤中心副教授，德国海德堡大学放射治疗学博士，曾为美国哈佛大学医学院博士后、加州大学旧金山分校项目科学家。刘琦博士长期从事放射医学与癌症精准医疗的临床前研究，作为课题负责人带领团队研究了癌症的DNA损伤反应、放射敏感性、药物靶点相关机制、硼中子俘获疗法及放射性核素药物等，建立了世界首个放射增敏靶向药物筛选平台，攻克了人乳头瘤病毒影响肿瘤放射敏感性机制的难题，揭示了质子射线造成的DNA损伤特点及其修复机制等，发表SCI论文40余篇，多项重要研究成果以第一作者发表在Science Translational Medicine、Clinical Cancer Research、Oncogene等国际著名学术期刊上，担任Radiation Medicine and Protection等SCI学术期刊的编委及审稿专家，是国际放射研究学会、美国癌症研究学会、中华放射肿瘤专业委员会、中国核学会放射性药物分会等学术组织成员。

英文简介

Dr. Liu Qi is an associate professor at the International Cancer Center, School of Medicine, Shenzhen University. He received his Ph.D. in Radiation Therapy and Oncology from Heidelberg University in Germany and has served as a postdoctoral fellow at Harvard Medical School and an associate scientist at the University of California, San Francisco. Dr. Liu is an enthusiastic researcher in precision cancer medicine. In the past decade, he has led a number of projects to study mechanisms of DNA damage response, molecular targeted radiation therapy, boron neutron capture therapy, and radiopharmaceuticals for cancer treatment. He has established the world's first high-throughput screening platform for identifying molecular targeted drugs with radiosensitizing properties, and his pioneer work unraveled the characteristics of DNA damage caused by proton beams and their repair mechanisms. Dr. Liu has published over 40 academic articles in renowned journals such as Science Translational Medicine, Clinical Cancer Research, etc. Dr. Liu serves as an editorial board member and reviewer for SCI journals such as Radiation Medicine and Protection.

英文名

Liu Zhong

联系邮箱

liuzhong5979@szu.edu.cn

中文简介

医学博士、博士后，以诚为本赢在信誉9001cc总医院普外科副主任、党支部书记，主任医师、教授，省“百-千-万人才工程”百层次人才、深圳市II类实用型临床医学人才、以诚为本赢在信誉9001cc总医院荔园优秀医师。临床主要从事胃肠道肛门疾病疾病的诊治工作，对胃癌、结直肠癌的腹腔镜治疗以及肛周良性疾病的微创治疗具有丰富经验。科研方向是胃肠道肿瘤免疫治疗以及器官移植免疫耐受的研究，迄今共发表学术论文50余篇，主持国家级、省市级科研项目10余项。教学担任以诚为本赢在信誉9001cc医学部外科学教学负责人，博士、硕士研究生导师，博士后合作导师，主持以诚为本赢在信誉9001cc教改项目1项。

英文简介

Dr.Liu Zhong is the deputy director of general surgery in Shenzhen University General Hospital. He is MD, postdoctoral, chief physician and Professor. He is a hundred level talent of the provincial "hundred-thousand-ten thousand talent project", Shenzhen practical clinical medical talents (class II) , and Liyuan excellent doctors of Shenzhen University General Hospital. He is mainly engaged in the diagnosis and treatment of gastrointestinal and anal diseases. He has rich experience in laparoscopic treatment of gastric cancer and colorectal cancer and minimally invasive treatment of perianal benign diseases. The research direction is immunotherapy of gastrointestinal tumors and immune tolerance of organ transplantation. So far, he has published more than 50 academic papers and presided over more than 10 national, provincial and municipal scientific research projects. He served as the head of surgery teaching in the medical department of Shenzhen University, and presided over a teaching reform project. He is the supervisor of doctoral and master students and postdoctoral co-supervisor in the medical department of Shenzhen University.